Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed

References

• Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005;13:219–27
   PubMed Web of Science ®Google Scholar
• Ballatori E, Roila F. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 2003;1:46
   PubMedGoogle Scholar
• Glaus A, Knipping C, Morant R, et al. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 2004;12:708–15
   PubMed Web of Science ®Google Scholar
• Osoba D, Zee B, Warr D, et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997;5:307–13
   Google Scholar
• Osoba D, Zee B, Pater J, et al. Determinants of postchemo-therapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997;15:116–23
   Google Scholar
• O’Brien BJ, Rusthoven J, Rocchi A, et al. Impact of chemotherapy-associated nausea and vomiting on patients’ functional status and on costs: survey of five Canadian centres. CMAJ 1993;149:296–302
   Google Scholar
• Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004;15:526–36
   Google Scholar
• Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103–9
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – an update. Support Care Cancer 2005;13: 80–4
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Antiemesis. Clinical practice guidelines in oncology – v.2.2006. Available from http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf [Last accessed 7 June 2006]
   Google Scholar
• American Society of Health-System Pharmacists.ASHP Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemo-therapy or Radiation Therapy or Undergoing Surgery. Am J Health Syst Pharm 1999;56:729–64
   PubMed Web of Science ®Google Scholar
• Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemo-therapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann Oncol 1998;9:811–19
   Google Scholar
• Griffin AM, Butow PN, Coates AS, et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemo-therapy in 1993. Ann Oncol 1996;7: 189–95
   Google Scholar
• Carelle N, Piotto E, Bellanger A, et al. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002;95:155–63
   PubMed Web of Science ®Google Scholar
• de Boer-Dennert M, de Wit R, Schmitz PI, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997;76: 1055–61
   Google Scholar
• Hofman M, Morrow GR, Roscoe JA, et al. Cancer patients’ expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center – Community Clinical Oncology Program study of 938 patients from community practices. Cancer 2004;101:851–7
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261–8
   PubMed Web of Science ®Google Scholar
• Liau CT, Chu NM, Liu HE, et al. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomes. Support Care Cancer 2005;13:277–86
   PubMed Web of Science ®Google Scholar
• Jordan K. Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy. Onkologie 2006;29:39–43
   PubMed Web of Science ®Google Scholar
• Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapyand radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17: 20–8
   Google Scholar
• Kris MG, Hesketh PJ, Herrstedt J, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2005;13:85–96
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Aapro MS, Roila F, Kataja VV. ESMO Minimum Clinical Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol 2005;16 (Suppl 1):i77–9
   PubMed Web of Science ®Google Scholar
• Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932–47
   PubMed Web of Science ®Google Scholar
• Aguilar EA, Figueiras MC, Cortes-Funes H, et al. Clinical practice guidelines on antiemetics in oncology. Expert Rev Anticancer Ther 2005;5:963–72
   PubMed Web of Science ®Google Scholar
• De Angelis V, Roila F, Sabbatini R, et al. Cancer chemotherapy-induced delayed emesis: antiemetic prescriptions in clinical practice [abstract]. Proc Am Soc Clin Oncol 2003;22:739
   Google Scholar
• Rubenstein EB, Litke SE, Jose MA. Chemotherapy-induced nausea and emesis in the 5HT3 era: a national survey of hematologists/oncologists [abstract]. Proc Am Soc Clin Oncol 2002;21:260b
   Google Scholar